Clinical trials: Plaque Psoriasis.
Psoriasis
A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528)
Middle Eastern subjects with moderate-to-severe chronic plaque psoriasis will be administered infusions of infliximab (Remicade) at 5 mg/kg of body weight at Weeks 0, 2, 6, 14, and 22.
- Trial name
- NCT00687362
- Testing
- Infliximab
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriasis
BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a randomized double blind, double dummy, active comparator controlled, parallel design study that is performed to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) compared to adalimumab to support…
- Trial name
- NCT02694523
- Testing
- risankizumab, adalimumab
- Volunteers
- 684 people
- Sponsor
- AbbVie
Psoriasis
A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g
This is an open label, multicenter study designed to evaluate the safety and tolerability of efalizumab administered subcutaneously at weekly doses of 1.0 mg/kg in subjects with plaque psoriasis who previously participated in…
- Trial name
- NCT00096603
- Testing
- Raptiva (efalizumab)
- Volunteers
- 450 people
- Sponsor
- Genentech, Inc.
Chronic Plaque Type Psoriasis
Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis
This study assessed efficacy of secukinumab, compared to ustekinumab, in patients that have plaque-type psoriasis
- Trial name
- NCT02074982
- Testing
- AIN457 300 mg, ustekinumab 45/90 mg
- Where
- 137 sites in United States, Australia and 22 more
- Volunteers
- 676 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
Subjects with a clinical diagnosis of plaque psoriasis with 10% to 20% of body surface area affected will be enrolled in the study.
- Trial name
- IDP-118 (NCT01670513)
- Testing
- IDP-118 Low Strength, IDP-118 High Strength
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Dow Pharmaceutical Sciences
Plaque-Type Psoriasis
A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis
The purpose of the study is to determine the efficacy and safety of two different forms of a topical steroid (clobetasol propionate) in patients with plaque-type psoriasis.
- Trial name
- NCT00852761
- Testing
- Olux-E Foam, Clobex lotion
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Stiefel, a GSK Company
Plaque-type Psoriasis
Safety Study of Ointment for the Treatment of Plaque-type Psoriasis
The purpose of this study is to determine how much drug is absorbed throughout the body after being applied to the skin.
- Trial name
- AN2728-PSR-104 (NCT01258088)
- Testing
- AN2728 Ointment, AN2728 Vehicle
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Moderate to Severe Chronic Plaque-Type Psoriasis
4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
CAIN457A2304E1 was an extension study to two phase III studies, CAIN457A2304 and CAIN457A2307 (core studies). This extension study planned to collect up to four years of long-term safety, tolerability and efficacy data of…
- Trial name
- NCT01640951
- Testing
- AIN457 150 mg, AIN457 300 mg
- Where
- 111 sites in United States, Austria and 13 more
- Volunteers
- 675 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis
Add-on Enstilar to Otezla therapy.
- Trial name
- NCT03587194
- Testing
- Otezla
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
Chronic Plaque Psoriasis, Nail Psoriasis
An Open Label Trial to Evaluate Efficacy and Safety of Roflumilast 0.3% Cream for Chronic Plaque and Nail Psoriasis
This is an open label trial in subjects ≥12 years of age and older with chronic plaque psoriasis and moderate to severe nail psoriasis.
- Trial name
- NCT07725822
- Testing
- Roflumilast 0.3% topical cream
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Modern Research Associates, PLLC
Psoriasis
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
This study is to evaluate the safety, the systemic exposure, and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-118 lotion in pediatric participants with moderate to severe plaque…
- Trial name
- NCT03988439
- Testing
- IDP-118 Lotion
- Where
- 9 sites in United States, Dominican Republic and 1 more
- Volunteers
- 16 people
- Sponsor
- Bausch Health Americas, Inc.
Moderate to Severe Plaque Psoriasis
Documentation of Humira in Psoriasis Patients in Routine Clinical Practice
Safety and Effectiveness of adalimumab (Humira) in Psoriasis Patients in Routine Clinical Practice.
- Trial name
- LOTOS (NCT01077232)
- Where
- 641 sites in Germany
- Volunteers
- 5,442 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriatic Plaque
A Study to Investigate Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis
The study is designed to investigate efficacy and safety of KBL697 in patients with Moderate Plaque Type Psoriasis. KBL697 has been developed as a potential new treatment for Psoriatic Plaque.
- Trial name
- NCT04911751
- Testing
- KBL697
- Where
- 10 sites in United States, Australia
- Volunteers
- 80 people
- Sponsor
- KoBioLabs
Plaque Psoriasis
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the potential of DFD01 spray to suppress the HPA (hypothalamic-pituitary-adrenal) axis as compared to Comp01 lotion when applied twice daily for 15 days.
- Trial name
- BDS1307 (NCT02070965)
- Testing
- DFD01 Spray, Comp01 Lotion
- Where
- 12 sites in United States
- Volunteers
- 75 people
- Sponsor
- Primus Pharmaceuticals
Psoriasis
A Intra-individual Comparison to Investigate the Efficacy and the Safety of LAS41004 Formulation in Mild to Moderate Psoriasis
Proof-of concept study to competitively investigate antipsoriatic efficacy and safety of a LAS41004 formulation vs active control No formal study hypothesis, but descriptive evaluation (PoC).
- Trial name
- Left/Right (NCT02180464)
- Testing
- LAS41004, control
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Almirall, S.A.
Psoriasis
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.
- Trial name
- POETYK-PSO-2 (NCT03611751)
- Testing
- BMS-986165, Apremilast
- Where
- 205 sites in United States, Australia and 14 more
- Volunteers
- 1,020 people
- Sponsor
- Bristol-Myers Squibb
Chronic Plaque-type Psoriasis
Serum Substance P, Neuropathic Pain, and Central Sensitization Across Treatment Groups in Chronic Plaque Psoriasis
The goal of this observational study is to better understand whether blood levels of Substance P are related to pain, itching, altered pain sensations, central sensitization, psoriasis severity, and quality of life in adults with…
- Trial name
- NCT07844772
- Testing
- IL-17 Inhibitor Therapy, Conventional Systemic Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Istanbul Training and Research Hospital
Moderate to Severe Plaque Psoriasis
A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece
This study estimates the treatment goal achievement rate, depicts the implementation of the Progressive Psoriasis Initiative (PPI) recommendations regarding treatment modifications and transitioning, and assesses patient…
- Trial name
- CONCORDIA (NCT02713295)
- Where
- 43 sites in Greece
- Volunteers
- 273 people
- Sponsor
- AbbVie
Psoriasis
Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab
The purpose of this study was to explore the effect of treatment with 300 mg or with 150 mg secukinumab (administered weekly for 4 weeks followed by four-weekly administration) on endothelial dysfunction and arterial stiffness…
- Trial name
- CARIMA (NCT02559622)
- Testing
- Secukinumab
- Where
- 23 sites in Germany
- Volunteers
- 151 people
- Sponsor
- Novartis Pharmaceuticals
Moderate to Severe Plaque Psoriasis
An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis
BCD-085 is an innovative drug, a monoclonal antibody against interleukin-17. The toxicity, safety, and pharmacokinetics of BCD-085 were investigated in animals, in phase I clinical study in healthy volunteers, and in phase III…
- Trial name
- BCD-085-7 (NCT03390101)
- Testing
- BCD-085 Q2W, BCD-085 Q4W
- Where
- Russia
- Volunteers
- 213 people
- Sponsor
- Biocad